Format

Send to

Choose Destination
Pancreatology. 2019 Jun;19(4):566-568. doi: 10.1016/j.pan.2019.05.459. Epub 2019 May 18.

First pancreatic perivascular epithelioid cell tumor (PEComa) treated by mTOR inhibitor.

Author information

1
Centre Hospitalier Universitaire de Nantes, Institut des Maladies de l'Appareil Digestif, Nantes, France.
2
Centre Hospitalier Universitaire de Nantes, Service d'Oncologie Pédiatrique, Nantes, France.
3
Centre Hospitalier Universitaire de Nantes, Service d'Anatomopathologie, Nantes, France.
4
Centre Hospitalier Universitaire de Nantes, Institut des Maladies de l'Appareil Digestif, Nantes, France. Electronic address: nicolas.musquer@chu-nantes.fr.

Abstract

BACKGROUND:

Perivascular epithelioid cell tumor, an extremely rare mesenchymal tumor, could be ubiquitous but rarely arises from pancreas. Surgery is considered the most appropriate treatment. Nevertheless, activation of mTOR pathway seems to be a common pathogenic event in PEComas paving the way to chemotherapy by mTOR inhibitor.

METHOD:

A 17 year-old man presented a hypervascular tumor of 55 mm, located in the head of pancreas without bile duct or pancreatic duct compression.

RESULTS:

Histopathology showed epithelioid cells with clear or focally granular eosinophilic cytoplasm with melanocytic (HMB-45, Melan-A) and myoid markers which confirmed diagnosis of PEComa. Given the absence of worrisome feature, we ruled out surgery and decided to initiate treatment with Sirolimus, an mTOR inhibitor. After 3.5 years, we showed a significant reduction in size of the tumor.

CONCLUSION:

This first case of pancreatic PEComa treated by mTOR inhibitor without surgery suggests a good efficiency of this therapy.

KEYWORDS:

Mesenchymal tumor; Pancreatic cancer; Treatment

PMID:
31130397
DOI:
10.1016/j.pan.2019.05.459

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center